“The ‘NHS Challenge’ is designed specifically for agencies that have strong experience in dealing with UK specific challenges,” says the executive steering group’s Eric Hansen.
“The ‘NHS Challenge’ is designed specifically for agencies that have strong experience in dealing with UK specific challenges,” says the executive steering group’s Eric Hansen.
PharmaTimes Media has announced the Medical & Scientific Excellence Awards as the latest addition to its highly prestigious portfolio of events – and now is the time to enter!
“There is always a danger that health issues are not kept to the fore” in negotiations, says Niall Dickson
Janssen says it is disappointed that NHS cost regulators are not backing NHS use of Darzalez (daratumumab) plus bortezomib and dexamethasone (DBd) for previously treated multiple myeloma in adults.
GlaxoSmithKline has sold rights to an experimental therapy being developed for psoriasis and dermatitis to Dermavant in a deal worth $330 million.
Zogenix has revealed top-line results from a second late-stage trial of its investigational Dravet syndrome drug ZX008, showing a significant reduction in seizures.
NHS Confederation chief executive Niall Dickson is warning that the NHS is “under intolerable strain”, after the latest performance data continue to show growing demand and missed targets.
Roche group Genentech has filed an application to market Venclexta in the US for acute myeloid leukemia (AML).
NHS funding for EUSA’s Pharma’s Qarziba has been approved to treat children with high-risk neuroblastoma.
AbbVie and Johnson & Johnson’s Imbruvica has failed to meet its key target in a late stage study assessing its use in patients with treatment-naïve diffuse large B-cell lymphoma.
Pfizer has announced a re-organisation of its operations into three distinct businesses.
NICE has published new guidelines recommending use of a chemical dye to assist neurosurgeons in removing brain tumours.
NHS England has appointed a specialist GP to encourage the spread of innovations that integrate health and social care throughout England.
Janssen has kicked off a Phase II/III programme assessing Tremfya in Crohn’s Disease.
The government has launched a £10 million research competition to encourage the development of novel approaches to combating antimicrobial resistance and improving infection prevention and control.